![]() Still, “I consider this issue a headache more than a problem,” he added.Īs for why this newly commercially available blood test could be an important step forward, Dr. “That is, the sensitivity of the test is the ability of the test to prove you have amyloid. “This disconnect means that many people with positive blood tests will not have ,” Dr. He noted that “almost half of people with normal cognition die with amyloid in their brains” and “ll patients with have amyloid in their brains.” Tesi, CEO and CMO of INmune Bio, a biotechnology company that aims to use elements of the immune system to fight cancer and Alzheimer’s disease, spoke to MNT about the pros and cons of a blood test focusing on detecting beta-amyloid. What do other experts think of this test?ĭr. We encourage anyone who receives a result suggestive of risk to confer with a physician to discuss next steps.” In addition to emerging therapies, growing science indicates that behavioral and other changes can influence risk (i.e., exercise, not smoking, socializing). “Early detection can help encourage the necessary discussions with a healthcare provider about steps to minimize risk. ![]() While the test is a starting point for evaluating the risk of Alzheimer’s, it is not a definitive diagnostic tool, and Quest Diagnostics encourages individuals who are concerned about their risk to confer with their healthcare provider. If they don’t click on this box, they can’t purchase the test,” the spokesperson further noted. “In addition, prior to purchase of the service online, a pop-up box appears that an individual must check on digitally to acknowledge they meet one of several specified risk factors. “We explain on that the test is for individuals who meet certain criteria, including family history, evidence of mild cognitive impairment, or prior brain trauma or head injury,” the Quest Diagnostics spokesperson told MNT. Test results reviewed by independent physiciansĪdditionally, individuals with results indicating a potential Alzheimer’s disease risk will be contacted by a physician from the independent network. ![]() Our test uses tandem mass spectrometry, a highly sensitive method.” ![]() A lower ratio of A-beta 42 to A-beta 40 in the brain is associated with a greater risk of developing Alzheimer’s disease. “Specifically, it measures two peptides of the amyloid-beta protein - A-beta 42 and A-beta 40 - to arrive at a ratio score. “This new consumer-initiated test utilizes the same expertise and technology as Quest Diagnostics’ clinical AD-Detect Amyloid Beta 42/40 Ratio test, an analytically validated blood test that aids in assessing the risk of Alzheimer’s disease, which we launched for physician ordering in early 2022,” they added. ![]() However, Quest’s AD-Detect™ Test brings a more accessible alternative, particularly beneficial for those experiencing cognitive decline, exhibiting mild cognitive impairment symptoms, or with a family history of Alzheimer’s.Ī company spokesperson from Quest Diagnostics spoke to Medical News Today, saying that “the AD-Detect Test for Alzheimer’s disease on is a starting point for evaluating risk of Alzheimer’s disease.” Traditionally, Alzheimer’s disease detection has relied on symptom screening followed by invasive and costly tests. How does the new blood test detect Alzheimer’s?īy allowing consumers to take control of their cognitive health assessment, Quest Diagnostics claims to facilitate a proactive approach to Alzheimer’s risk identification. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |